This top fund manager just called these leading ASX shares a buy

WAM thinks that these two ASX shares are buys.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A stopwatch ticking close to the 12 where the words on the face say 'Time to Buy'.

Image source: Getty Images

Key points

  • Fund manager Wilson Asset Management (WAM) has outlined two ASX shares with potential
  • The first stock is pathology business Australian Clinical Labs which is benefiting from the high level of COVID testing
  • The second company is building and restoration services Johns Lyng which is growing market share and opening up new growth opportunities

Leading fund manager Wilson Asset Management (WAM) has named two ASX shares in its portfolios that it thinks are buys.

Every month, WAM talks about some of the businesses that have performed well and outlines the bullish factors for thinking about the stocks.

Two of the featured ASX shares this month comes from WAM Research Limited (ASX: WAX) and WAM Capital Limited (ASX: WAM), which sometimes target opportunities from the smaller end of the ASX, like these two:

Australian Clinical Labs Ltd (ASX: ACL)

Australian Clinical Labs is described as a leading provider of pathology services in Australia, with 86 accredited laboratories performing services for more than 8 million people annually.

In December, Australian Clinical Labs upgraded its expectations for the FY22 first-half net profit after tax (NPAT) to between $116.3 million to $128 million. This was increased from the previous guidance of between $86.3 million to $94.9 million.

The fund manager notes that the ASX share is experiencing strong demand for coronavirus testing, particularly during the Omicron variant outbreak and recently completed the acquisition of Medlab Pathology, doubling its market share to 20.4% in New South Wales.

WAM thinks that Australian Clinical Labs is a high-quality pathology business that can continue to grow organically through market share gains, due to its "superior technology and processes". The fund manager notes that Australian Clinical Labs has a very strong balance sheet and it also sees the potential for acquisitions in the future that can add to profit.

Johns Lyng Group Ltd (ASX: JLG)

Another ASX share that WAM likes is Johns Lyng which provides building and restoration services across Australia for properties and contents damaged by insurable events, including impact, weather, and fire events.

It operates in all major metropolitan areas and in high-risk regional areas, such as Far North Queensland.

WAM pointed out that in December, the company announced the acceleration of its US growth strategy through the acquisition of Reconstruction Experts, a leading provider of insurance-focused vendor managed repairs services for US$144 million.

This acquisition, considered highly strategic, adds to the company's earnings per share (EPS) and equated to 7.8x earnings before interest, tax, depreciation and amortisation (EBITDA) for the 12 months to 30 June 2021.

The fund manager decided to invest in Johns Lyng Group based on the view that as the largest and most sophisticated provider of emergency building works, the company will continue to grow through market share gains and acquisition.

WAM believes that with the recent acquisition, the company has added another material growth pillar that will underpin longer-term aspirations and earnings growth.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Clinical Labs Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Opinions

Woman happy and relaxed on a sofa at a shop.
Opinions

Would Warren Buffett buy this ASX 200 share?

Would the talisman of Berkshire Hathaway like this globally-growing share?

Read more »

A group of six young people doing the limbo on a beach, indicating oversold shares that can not go any lower.
Opinions

Is the worst over for Xero shares? Here's what the chart is showing

Signs are emerging that Xero shares may have found a floor...

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Opinions

Want to double your money in 2026? This is what I'd buy

High-quality ASX tech stocks are now trading well below prior highs.

Read more »

A bemused woman holds two presents of different sizes and colours and tries to make a choice.
Opinions

My ASX share portfolio: Overcoming a common investing mistake

Can you have too many shares?

Read more »

Red buy button on an Apple keyboard with a finger on it.
Opinions

If I had $10,000, this is the ASX stock I'd buy right now

WiseTech’s pullback may offer a rare entry into a global software leader.

Read more »

A group of people in suits and hard hats celebrate the rising share price with champagne.
Resources Shares

Up 67% in a year! The red-hot South32 share price is smashing BHP, Rio and Fortescue

Here's why I think the miner could outpace some of its peers in 2026.

Read more »

Woman in business suit holds both hands out with a question mark above each hand.
Opinions

2 ASX 300 shares I'm close to buying next!

These ASX 300 shares look like a great buy to me today!

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Growth Shares

This could be the best ASX 300 stock buy today!

This seems like a great time to invest.

Read more »